Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 498

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

Bivalirudin Started during Emergency Transport for Primary PCI

Open access
Steg, Philippe Gabriel, van 't Hof, Arnoud, Hamm, Christian W., Clemmensen, Peter, Lapostolle, Frédéric, Coste, Pierre, Ten Berg, Jurrien, Van Grunsven, Pierre, Eggink, Gerrit Jan, Nibbe, Lutz, Zeymer, Uwe, Campo dell' Orto, Marco, Nef, Holger, Steinmetz, Jacob, Soulat, Louis, Huber, Kurt, Deliargyris, Efthymios N., Bernstein, Debra, Schuette, Diana, Prats, Jayne, Clayton, Tim, Pocock, Stuart, Hamon, Martial, Goldstein, Patrick·2013·New England Journal of Medicine

Abstract

BACKGROUND: Bivalirudin, as compared with heparin and glycoprotein IIb/IIIa inhibitors, has been shown to reduce rates of bleeding and death in patients undergoing primary percutaneous coronary intervention (PCI). Whether these benefits persist in contemporary practice characterized by prehospital initiation of treatment, optional use of glycoprotein IIb/IIIa inhibitors and novel P2Y12 inhibitors, and radial-artery PCI access use is unknown. METHODS: We randomly assigned 2218 patients with ST-segment elevation myocardial infarction (STEMI) who were being transported for primary PCI to receive either bivalirudin or unfractionated or low-molecular-weight heparin with optional glycoprotein IIb/IIIa inhibitors (control group). The primary outcome at 30 days was a composite of death or major bleeding not associated with coronary-artery bypass grafting (CABG), and the principal secondary outcome was a composite of death, reinfarction, or non-CABG major bleeding. RESULTS: Bivalirudin, as compared with the control intervention, reduced the risk of the primary outcome (5.1% vs. 8.5%; relative risk, 0.60; 95% confidence interval [CI], 0.43 to 0.82; P=0.001) and the principal secondary outcome (6.6% vs. 9.2%; relative risk, 0.72; 95% CI, 0.54 to 0.96; P=0.02). Bivalirudin also reduced the risk of major bleeding (2.6% vs. 6.0%; relative risk, 0.43; 95% CI, 0.28 to 0.66; P<0.001). The risk of acute stent thrombosis was higher with bivalirudin (1.1% vs. 0.2%; relative risk, 6.11; 95% CI, 1.37 to 27.24; P=0.007). There was no significant difference in rates of death (2.9% vs. 3.1%) or reinfarction (1.7% vs. 0.9%). Results were consistent across subgroups of patients. CONCLUSIONS: Bivalirudin, started during transport for primary PCI, improved 30-day clinical outcomes with a reduction in major bleeding but with an increase in acute stent thrombosis. (Funded by the Medicines Company; EUROMAX ClinicalTrials.gov number, NCT01087723.).

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1311096

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 498

Metadata

Authors
Steg, P. G., van 't Hof, A., Hamm, C. W., Clemmensen, P., Lapostolle, F., Coste, P., Ten Berg, J., Van Grunsven, P., Eggink, G. J., Nibbe, L., Zeymer, U., Campo dell' Orto, M., Nef, H., Steinmetz, J., Soulat, L., Huber, K., Deliargyris, E. N., Bernstein, D., Schuette, D., Prats, J., Clayton, T., Pocock, S., Hamon, M., & Goldstein, P.
Venue
New England Journal of Medicine
Published
2013-12-05
Volume
369
Issue
23
Pages
2207-2217
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2142825093
Cited by
498
References
22
FWCI
52.33
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Bivalirudin Started during Emergency Transport for Primary PCI. https://app.cochat.ai/papers/10.1056/nejmoa1311096
The paper
Steg, P. G., van 't Hof, A., Hamm, C. W., Clemmensen, P., Lapostolle, F., Coste, P., Ten Berg, J., Van Grunsven, P., Eggink, G. J., Nibbe, L., Zeymer, U., Campo dell' Orto, M., Nef, H., Steinmetz, J., Soulat, L., Huber, K., Deliargyris, E. N., Bernstein, D., Schuette, D., . . . Goldstein, P. (2013). Bivalirudin Started during Emergency Transport for Primary PCI. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1311096

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.